Asia Pacific
-
Chinese cancer immunotherapy drug producer parks over half of the deal with cornerstone investors -
In this table, GlobalCapital Asia offers a glimpse of the bond deals that are in the works
-
-
The follow-on public offer, in line with 144A rules, will fund the group's expansion
-
Immediate funding needs are driving companies to the debt market despite weak conditions
-
This round-up focuses on protests in major Chinese cities and fresh impetus for the property sector
-
In this table, GlobalCapital Asia offers a glimpse of the bond deals that are in the works
-
Gaush Meditech is seeking about $80m, and Weilong Global roughly $200m
-
This round-up focuses on new efforts to shore up the property sector with at least $130bn in support
-
In this table, GlobalCapital Asia offers a glimpse of the bond deals that are in the works
-
Tightening of covenants expected for new bonds
-
Investors supported the deal, which allowed the group to replenish its funding at a lower cost
